BriaCell Therapeutics ((TSE:BCT)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BriaCell Therapeutics is conducting a study titled ‘Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians’ Choice in Advanced Metastatic Breast Cancer.’ The study aims to evaluate the overall survival of patients with advanced metastatic breast cancer using the Bria-IMT regimen combined with a checkpoint inhibitor, Retifanlimab, compared to treatments chosen by physicians. This research is significant as it targets patients with no approved alternative therapies, potentially offering new hope for those in advanced stages of breast cancer.
The study is testing the Bria-IMT regimen, which includes the biological agent SV-BR-1-GM, and drugs such as Cyclophosphamide, Interferon, and Retifanlimab. These interventions are designed to enhance immune response and improve patient outcomes in breast cancer treatment.
This Phase 3 study is interventional, with a randomized and parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
The study began on September 25, 2023, and the primary completion date is yet to be determined. The last update was submitted on October 21, 2025, indicating ongoing progress and adjustments as the study evolves.
For investors, this study could influence BriaCell Therapeutics’ stock performance positively if the results show significant improvement in patient outcomes. The competitive landscape in breast cancer treatment is robust, but a successful trial could position BriaCell favorably against competitors.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.